Pabinafusp alfa

N/A

Report date: 2025/03/13 14:20:03

Base Information

Drug NamePabinafusp alfa

Drug Alias NameRecombinant iduronate-2-sulfataseanti-fR1 humanized monoclonal antibody, fused with human iduronate-2-sulfataseJR-141

ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzymeBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionGlycosaminoglycan degradersTransferrin receptor protein 1 modulators

TargetsGlycosaminoglycanTransferrin receptor protein 1

Therapy Area/IndicationsMucopolysaccharidosis II

Global Approved IndicationsMucopolysaccharidosis II

Approved Indications in ChinaN/A

Original Approved Country/TerritoryJapan

Original Approved Date2021/03/23

Country/TerritoryUnited StatesPolandItaly +[12]

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesJcr Pharmaceuticals Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesJcr Pharmaceuticals Co Ltd

Inactive CompaniesN/A

Active IndicationsMucopolysaccharidosis II

Inactive IndicationsN/A

Other Information

ATC CodeA16AB09